Cabaletta Bio (CABA)
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmun...
- Open
- 2.820
- High
- 2.835
- Low
- 2.735
- Prev. Close
- 2.800
- Volume
- 3.53M
- Turnover
- 9.83M
- Avg Price
- 2.788
- Bid/Ask Ratio
- --
- Amplitude
- 3.57%
- 52wk High
- 4.230
- Volume Ratio
- 1.56
- Turnover Ratio
- 2.55%
Cabaletta Bio Analyst Rating
View moreForecast & Rating
Jun 12, 2026Price forecast
$13.38379.39%
Forecast & RatingBuy
10analysts
- Strong buy70.00%
- Buy10.00%
- Hold20.00%
- Sell0.00%
- Strong sell0.00%
News
- TradingView · Aug 8 at 02:20 AM
Cabaletta Bio, Inc. Stock 12‑Month Price Target Raised to $14.71, Implies 427% Upside
- Global Report · Aug 4 at 04:17 AM
Behind the Scenes of Jersey Mike's Blockbuster IPO and the Mid-Cap Shuffle
- Global Report · Jul 22 at 04:17 AM
Surviving the Margins: How Niche Tech and Traditional Giants Are Navigating the 2026 Capital Squeeze
- Tip Ranks · Jul 10 at 02:48 PM
3 High-Risk, High-Reward Stocks to Buy Now for Strong Upside, According to Analysts
- Unusual Whales · Jun 3 at 06:01 AM
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
- Tip Ranks · May 14 at 02:15 PM
Analyst Reiterates Buy on Cabaletta Bio, Citing Strong Non-Preconditioned PV Data, Scalable Manufacturing, and Multiple Upcoming Catalysts
